Net Income of Watson Primary Quarter Increased to 87%

Watson Pharmaceuticals, Inc. confirmed net income for this first quarter 2012 improved 87 percent to actually $208.8 million or $1.64 per diluted impart upon the non-GAAP basis, when compared with $111.9 million or $0.89 per diluted carefully impart to begin with part 2011. On a GAAP source, net earnings improved 74 percent to $1.5 billion, when compared with $876.5 million to begin with quarter 2011. GAAP income per diluted share for first section 2012 have been $0.43, when compared with $0.36 in the before season period.

For these first quarters 2012, aligned EBITDA improved 70% to actually $367.2 million, when compared with $215.9 million for the first quarter 2011. Income and marketable securities has been $182.2 million at the time of March 31, 2012. Refer to the attached conciliation platform for changes to actually GAAP income.

Paul Bisaro, President and CEO said that, “Significant double-digit earning development across our three corporations such as Global Generics, Global Brands and Anda distribution – drove an 84 percent rise in non-GAAP income per share, as well as a $151 million rise in Adjusted EBITDA".